Legal status · Australia
Is BGM0504 legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. BGM0504 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
BGM0504 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 2 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the BGM0504 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
BGM0504 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What BGM0504 is
A tirzepatide-derived dual agonist that beat semaglutide 1 mg on glycated haemoglobin and weight in a 64 person phase 2. Its phase 3 obesity result, widely quoted at 19.3 percent weight loss, exists only as a company press release and has not been published.
BGM0504 comes from BrightGene Bio-Medical in Suzhou and is explicitly derived from tirzepatide. The published design paper says so: molecular dynamics simulations identified a salt bridge between the parent peptide and both receptors, the acylation side chain was repositioned on that basis, and the resulting molecule showed two to three times the agonist activity of tirzepatide in vitro while keeping a long plasma half-life.
Mechanism: A dual agonist at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, the same receptor pair tirzepatide acts on, engineered from the tirzepatide scaffold. The published optimisation work used molecular dynamics simulation to identify a salt bridge between the parent peptide and both receptors at residue K20 that was not visible in the cryo-electron microscopy structures, then repositioned the fatty acid acylation side chain to preserve it.
Regulatory history: Not approved anywhere. Multiple phase 3 trials are recruiting in China and Indonesia, and a tablet formulation is in phase 1. The phase 3 obesity result announced in May 2026 has not been published in a peer-reviewed journal as of this review.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for BGM0504 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
BGM0504 in other countries
Frequently asked questions
Is BGM0504 legal in Australia?
No. BGM0504 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Can I buy BGM0504 in Australia?
No approved product exists to buy. In Australia BGM0504 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is BGM0504 TGA approved?
No. In Australia BGM0504 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Not approved anywhere. Multiple phase 3 trials are recruiting in China and Indonesia, and a tablet formulation is in phase 1. The phase 3 obesity result announced in May 2026 has not been published in a peer-reviewed journal as of this review.. On the evidence, 2 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for BGM0504 live on its compound profile.
BGM0504 profileThis page is general information about the regulatory status of BGM0504 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.